Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Logo for

J. Biol. Chem. 277 (16): 13583-13588

© 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

Identification of a Soluble Form Phospholipase A2 Receptor as a Circulating Endogenous Inhibitor for Secretory Phospholipase A2*

Ken-ichi Higashino, Yasunori Yokota, Takashi Ono, Shigeki Kamitani, Hitoshi Arita, and Kohji HanasakiDagger

From the Shionogi Research Laboratories, Shionogi & Co., Ltd. 12-4 Sagisu, 5-Chome, Fukushima-ku, Osaka 553-0002, Japan

Venomous snakes have various types of phospholipase A2 inhibitory proteins (PLIs) in their circulatory system to protect them from attack by their own phospholipase A2s (PLA2s). Here we show the first evidence for the existence of circulating PLI against secretory PLA2s (sPLA2s) in mammals. In mouse serum, we detected specific binding activities of group IB and X sPLA2s, which was in contrast with the absence of binding activities in serum prepared from mice deficient in PLA2 receptor (PLA2R), a type I transmembrane glycoprotein related to the C-type animal lectin family. Western blot analysis after partial purification with group IB sPLA2 affinity column confirmed the identity of serum sPLA2-binding protein as a soluble form of PLA2R (sPLA2R) that retained all of the extracellular domains of the membrane-bound receptor. Both purified sPLA2R and the recombinant soluble receptor having all of the extracellular portions blocked the biological functions of group X sPLA2, including its potent enzymatic activity and its binding to the membrane-bound receptor. Protease inhibitor tests with PLA2R-overexpressing Chinese hamster ovary cells suggested that sPLA2R is produced by cleavage of the membrane-bound receptor by metalloproteinases. Thus, sPLA2R is the first example of circulating PLI that acts as an endogenous inhibitor for enzymatic activities and receptor-mediated functions of sPLA2s in mice.

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 81-6-6455-2104; Fax: 81-6-6458-0987; E-mail:

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

Deficiency of Phospholipase A2 Receptor Exacerbates Ovalbumin-Induced Lung Inflammation.
S. Tamaru, H. Mishina, Y. Watanabe, K. Watanabe, D. Fujioka, S. Takahashi, K. Suzuki, T. Nakamura, J.-e. Obata, K. Kawabata, et al. (2013)
J. Immunol. 191, 1021-1028
   Abstract »    Full Text »    PDF »
Secreted phospholipase A2 revisited.
M. Murakami, Y. Taketomi, H. Sato, and K. Yamamoto (2011)
J. Biochem. 150, 233-255
   Abstract »    Full Text »    PDF »
Mapping the Region of the {alpha}-Type Phospholipase A2 Inhibitor Responsible for Its Inhibitory Activity.
K. Okumura, A. Ohno, M. Nishida, K. Hayashi, K. Ikeda, and S. Inoue (2005)
J. Biol. Chem. 280, 37651-37659
   Abstract »    Full Text »    PDF »
Autocrine and Paracrine Transcriptional Regulation of Type IIA Secretory Phospholipase A2 Gene in Vascular Smooth Muscle Cells.
A. Jaulmes, B. Janvier, M. Andreani, and M. Raymondjean (2005)
Arterioscler Thromb Vasc Biol 25, 1161-1167
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882